Yahoo Finance

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The firm notes that Phase 1 ATTR-CM data for nex-z compare well vs. historical data shown by silencers and stabilizers, despite having a greater proportion of patients with more severe disease. Wells thinks this should bode well for Phase 3 success.

Don't Miss out on Research Tools:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NTLA:

• Intellia Therapeutics price target raised to $91 from $88 at Chardan

• Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer

• Intellia Therapeutics price target lowered to $55 from $76 at Barclays

• Intellia Therapeutics Reports Q3 2024 Financial Progress

• Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch